Hémianopsie bitemporale révélatrice d’une atteinte toxique sévère à l’éthambutol

Scemama, E Boulanger; Hoang, P. Le

doi:10.1016/j.jfo.2012.12.008

Cited by 12 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical characteristics of ethambutol induced toxic optic neuropathy (EON) include painless loss of vision and a centrocecal or bitemporal defect in the visual field (Melamud et al, 2003;Boulanger et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Ethambutol induced toxic optic neuropathy - A retrospective study in a tertiary eye care centre in Southern India

Shanmugam,

Sajja,

Kowsalya

et al. 2022

Nep J Oph

View full text Add to dashboard Cite

Introduction: Ethambutol is an antibiotic used as a first line drug in the treatment of tuberculosis and a vision threatening side effect of EMB is ethambutol-induced optic neuropathy (EON). The aim of the study is to create awareness about the potentiality of ethambutol to cause ethambutol-induced optic neuropathy, careful monitoring of dose and patient education. Materials and methods: A retrospective observational study of 14 patients whose complete Anti- tubercular treatment records could be retrieved were included. Epidemiological data including age, sex, systemic illness were recorded. Duration between optic nerve toxicity , usage of ethambutol and the drug dosage were noted. Best corrected visual acuity, anterior segment examination including pupils, extraocular movements, colour vision, central fields and fundus examination were evaluated. The patients were followed up at one and three month intervals. Results: Associated systemic illness was found to be a confounding factor for the development of ethambutol-induced optic neuropathy. 57% of patients had diabetes mellitus followed by hypertension (14.2%), renal disease (7.1%). The average daily dose of Ethambutol ingested was 1078.5 mg (21 mg/kg) and this high dose could have been the primary cause for development of ethambutol-induced optic neuropathy. Vision ranged from total blindness to mild visual impairment and poor recovery of vision was noted even after discontinuing ethambutol. Conclusion: Only a minority of patients showed improvement in visual function following discontinuation of ethambutol and the toxicity was found to be dose-dependent. Patients with comorbidities like renal impairment and diabetes mellitus appeared to be at greater risk. Ophthalmological examination before commencing treatment and periodic evaluation thereafter is mandatory.

show abstract

Section: Introductionmentioning

confidence: 99%

Ethambutol induced toxic optic neuropathy - A retrospective study in a tertiary eye care centre in Southern India

Shanmugam,

Sajja,

Kowsalya

et al. 2022

Nep J Oph

View full text Add to dashboard Cite

show abstract

“…Soon after its discovery in 1960s (Forbes et al, 1962), EMB was reported to cause changes in the optic nerve structure that result into optic neuropathy. Damage to the optic nerve structure is one of the most serious conditions because of the inability of the fibres to regenerate (Tawse et al, 2014), posing a risk of permanent and potentially severe loss of vision (Boulanger et al, 2013). Optic nerve consists of the myelinated axons of the retinal ganglion cells (de Lima et al, 2012), these mediate for the special sense of vision via the Special somatic afferent fibre (Watson, 2014).…”

Section: Introductionmentioning

confidence: 99%

Role of oligodendrocytes in reversing ethambutol induced optic neuropathy

Owembabazi¹,

Ahumuza²,

Ochieng³

et al. 2020

Anat. J. Afr.

View full text Add to dashboard Cite

Ethambutol is one of the first line drugs for treating tuberculosis. Its toxic effects on the optic nerve are majorly classified as reversible. However, worsening of vision and permanent vision loss after ethambutol discontinuation is also documented. To determine the effect of ethambutol toxicity on oligodendrocytes at different periods of treatment. Twenty-five male adult wistar rats of 110-130g average weight were housed in cages, exposed to 12-hour of dark and light cycles. After one week of acclimatization, five animals were randomly selected and sacrificed prior to ethambutol treatment for the control group (week 0). The remaining 20 animals were each orally administered 100mg/kg/day ethambutol. Five animals were randomly picked and sacrificed at the end of first, second, third, and fourth week of ethambutol treatment. There was no statistically significant difference in the number of oligodendrocyte cells obtained at the different stages of ethambutol treatment. Oligodendrocytes are not vulnerable to ethambutol toxicity for at least one month and they play a key role in reversing ethambutol induced neuropathy through myelin sheaths reconstruction. Key Words: Ethambutol, Oligodendrocytes, Optic Nerve, Optic Neuropathy.

show abstract

“…The insidious onset and slow progression of the symptoms often delay early detection, and hence, there is a consequent delay in its management. Central scotoma is the most common visual field defect, but bitemporal defects[ 12 13 ] or peripheral field constriction have also been reported. [ 14 ] Dyschromatopsia (abnormal color perception) can be the initial symptom in some patients.…”

mentioning

confidence: 99%

Ocular toxicity with ethambutol therapy: Timely recaution

Koul

2015

Lung India

View full text Add to dashboard Cite

Hémianopsie bitemporale révélatrice d’une atteinte toxique sévère à l’éthambutol

Cited by 12 publications

References 13 publications

Ethambutol induced toxic optic neuropathy - A retrospective study in a tertiary eye care centre in Southern India

Ethambutol induced toxic optic neuropathy - A retrospective study in a tertiary eye care centre in Southern India

Role of oligodendrocytes in reversing ethambutol induced optic neuropathy

Ocular toxicity with ethambutol therapy: Timely recaution

Contact Info

Product

Resources

About